Hero Image

Obesity is a function of biology.

ERX Pharmaceuticals Inc. is developing first-in-class leptin sensitizers for the treatment of obesity and related diseases based on a new understanding of the science of obesity.
obese man smiling and talking on phone


ERX is developing first-in-class leptin sensitizers to address unmet needs in the treatment of obesity.

Learn More

Metabolic Diseases

Metabolic Diseases

Insensitivity to leptin signaling contributes to a range of metabolic diseases, which may be addressable by leptin sensitizers.

Learn More

Hypothalamus Extended
37 catens outline copyCreated with Sketch.

Research + Development

Targeting Leptin Resistance

Leptin signaling plays a critical role in the body’s regulation of food intake and energy expenditure. ERX believes that improving leptin sensitivity can yield significant clinical benefits across a range of metabolic diseases, including obesity.
dna-outline-94Created with Sketch.


Drug Discovery and Development

ERX has several drug candidates in the pipeline, from ERX-1000 currently in the clinic, to additional compounds in preclinical or discovery stages.
Board meeting

Scientific Advisory Board

ERX is supported by an internationally renowned group of engaged scientific advisors who are experts in the fields of leptin biology and obesity drug discovery.

Learn More


News & Events

May 2019
ERX Pharmaceuticals Announces Appointment of Chief Medical Officer Barbara Troupin, MD, MBA and Chief Financial Offer Jonathan Lieber, MBA.